Skip to content

Ironwood Pharmaceuticals Inc

IRWD· Nasdaqxbrl foundCIK 1446847

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -0.41%
Market cap
$801.27M
165.55M shares
Filings
1,031
$133.04M
Q3 2026−15.7% FY25 yoy
$59.84M
Q3 2026+2,629.2% FY25 yoy
$93.13M
Q3 2026+5.8% FY25 yoy
$127.01M
FY 2025derived+22.8% FY25 yoy
$0.36
Q3 2026+1,400.0% FY25 yoy
$86.38M
Q3 2026+143.3% FY25 yoy
$801.27M
5.4×
2.0×
—
—
—

Twelve months to Sep 30, 2026 · derived

Price

$4.84+67.47%+$1.95past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$296.15MFY 2025
$442.74M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$296,151,000reported
FY 20242024-12-31$351,410,000reported
FY 20232023-12-31$442,735,000reported
FY 20222022-12-31$410,596,000reported
FY 20212021-12-31$413,753,000reported
FY 20202020-12-31$389,523,000reported
FY 20192019-12-31$428,413,000reported
FY 20182018-12-31$346,639,000reported
FY 20172017-12-31$298,276,000reported
FY 20162016-12-31$273,957,000reported
FY 20152015-12-31$149,555,000reported
FY 20142014-12-31$76,436,000reported

Capital returns

Dividends and buybacks · FY2021 to FY2022
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2022—$126.39M$126.39M—154.16M sh−3.2%46.2%
FY2021—$24.13M$24.13M—159.22M sh−1.1%9.2%

Segments

Products
Revenue by Products, FY2018 to FY2025FY2018Collaborative arrangements revenue · FY2018 · $272.84MCollaborative arrangement, other agreements · FY2018 · $1.23MProduct revenue, net · FY2018 · $3.45MSale of active pharmaceutical ingredient · FY2018 · $70.36MFY2019Collaborative arrangements revenue · FY2019 · $379.65MCollaborative arrangement, other agreements · FY2019 · $1.85MSale of active pharmaceutical ingredient · FY2019 · $48.76MFY2020Collaborative arrangements revenue · FY2020 · $381.55MCollaborative arrangement, other agreements · FY2020 · $1.34MSale of active pharmaceutical ingredient · FY2020 · $7.98MFY2021Collaborative arrangements revenue · FY2021 · $412.78MCollaborative arrangement, other agreements · FY2021 · $1.76MSale of active pharmaceutical ingredient · FY2021 · $969.00KFY2022Collaborative arrangements revenue · FY2022 · $410.60MCollaborative arrangement, other agreements · FY2022 · $1.82MFY2023Collaborative arrangements revenue · FY2023 · $442.74MCollaborative arrangement, other agreements · FY2023 · $2.48MFY2024Collaborative arrangements revenue · FY2024 · $351.41MCollaborative arrangement, other agreements · FY2024 · $734.00KFY2025Collaborative arrangements revenue · FY2025 · $296.15MCollaborative arrangement, other agreements · FY2025 · $87.00K
LineFY2025ShareChange
Collaborative arrangements revenue$296.15M100%−15.7%
Collaborative arrangement, other agreements$87.00K0.0%−88.1%
Product revenue, net———
Sale of active pharmaceutical ingredient———
Total$296.15M

From the 10-K filed Feb 26, 2026IRWD

Pharmaceutical preparations

Ironwood Pharmaceuticals Inc is the 68th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Ironwood Pharmaceuticals Inc · CIK 1446847 · Engraved from SEC EDGAR